Iovance Biotherapeutics Inc. Common Stock (IOVA)
Stock · NASDAQ · Health Care
$13.62as of 10/16/2026
Price chart
Active signals
Support level
$3.88
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
IOVA Signal Track Record
How signals performed across all stocks →What IOVA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -6.3% | 43% | September 29, 2026 |
| Bollinger Band Breakout | 23 | +8.0% | 61% | September 16, 2026 |
| Bollinger Band Breakdown | 20 | -6.3% | 40% | October 29, 2025 |
| 200-Day Moving Average TouchActive now | 12 | +1.2% | 50% | February 5, 2026 |
| Any 20-session window (baseline) | -3.3% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 975
- Website
- www.iovance.com/
Fundamentals
- 1-day range
- $14.1$15.11
- Market cap
- $2.77B
- P/E (trailing)
- —
- P/E (forward)
- -62.53
- EPS (trailing)
- $-0.72
- Dividend yield
- —
- Beta
- 0.82
- Avg. volume
- 17.80M
52-week range
$1.76$15.3
Next earnings: November 5, 2026 · EPS estimate $-0.09confirmed
Forecasts
10 analyst ratings
Buy 80%
Hold 20%
Sell 0%
1-year price forecast
High
$20
+46.8%
Median
$13.5
-0.9%
Low
$6
-55.9%
Iovance Biotherapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
- TARSTarsus Pharmaceuticals Inc. Common Stock$68.07▼ 4.11%Market cap $2.81BP/E —$53.89$91.53
- BEAMBeam Therapeutics Inc. Common Stock$23.47▼ 5.10%Market cap $2.81BP/E —$20.23$38.26
- KODKodiak Sciences Inc Common Stock$85.75▼ 2.69%Market cap $2.84BP/E —$10.94$104
- BCRXBioCryst Pharmaceuticals Inc. Common Stock$7.79▼ 2.87%Market cap $2.36BP/E —$6.23$11.22
- ADMAADMA Biologics Inc Common Stock$10.68▼ 0.47%Market cap $2.34BP/E 13.67$7.21$20.46
- VCELVericel Corporation Common Stock$40.13▼ 2.17%Market cap $2.29BP/E 85.09$28.95$49.32
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.81B | — | $68.07 | ▼ 4.11% | $53.89$91.53 |
| BEAM Beam Therapeutics Inc. Common Stock | $2.81B | — | $23.47 | ▼ 5.10% | $20.23$38.26 |
| KOD Kodiak Sciences Inc Common Stock | $2.84B | — | $85.75 | ▼ 2.69% | $10.94$104 |
| BCRX BioCryst Pharmaceuticals Inc. Common Stock | $2.36B | — | $7.79 | ▼ 2.87% | $6.23$11.22 |
| ADMA ADMA Biologics Inc Common Stock | $2.34B | 13.67 | $10.68 | ▼ 0.47% | $7.21$20.46 |
| VCEL Vericel Corporation Common Stock | $2.29B | 85.09 | $40.13 | ▼ 2.17% | $28.95$49.32 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Yahoo · 9/18/2026
- 4 Biotech Stocks to Watch as Potential Takeover TargetsYahoo · 9/18/2026
- Why Did CRWD, OKTA, IOVA Shares Climb To 52-Week Highs Today?Yahoo · 9/18/2026
- IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside Potential - Here’s WhyYahoo · 9/17/2026
- Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15Benzinga · 9/17/2026
- This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September RallyYahoo · 9/17/2026
- IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’Yahoo · 9/15/2026
- CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline PivotYahoo · 9/15/2026
Insider Activity
Insider Actions →Acquired
559.8K
Disposed
38.1K
- Daniel Gordon Kirby · August 10, 2026 · Option Exercise10.0K
- Daniel Gordon Kirby · August 10, 2026 · Tax Withholding2.4K @ $6.4
- Corleen M. Roche · August 6, 2026 · Option Exercise50.0K
- Corleen M. Roche · August 6, 2026 · Tax Withholding21.2K @ $6.21
- Dukes Iain D. · June 16, 2026 · Grant180.6K
- Athena Countouriotis · June 16, 2026 · Grant90.3K
- Raj K. Puri · June 16, 2026 · Grant15.0K
- Maynard Ryan D · June 16, 2026 · Grant90.3K
- WEISER MICHAEL · June 16, 2026 · Grant90.3K
- Frederick G. Vogt · June 5, 2026 · Option Exercise15.6K
- Frederick G. Vogt · June 5, 2026 · Tax Withholding6.6K @ $4.23
- Finckenstein Friedrich Graf · June 5, 2026 · Option Exercise7.8K
- Finckenstein Friedrich Graf · June 5, 2026 · Tax Withholding4.0K @ $4.23
- Raj K. Puri · June 5, 2026 · Option Exercise9.8K
- Raj K. Puri · June 5, 2026 · Tax Withholding3.8K @ $4.23
Institutional Ownership
March 31, 2026
- Total shares held
- 258.73M
- Total value held
- $874.49M
- Institutional holders
- 280
Top holders this quarter
- Unknown31.08M
- Unknown28.97M
- Unknown17.45M
- Unknown16.62M
- Unknown13.69M
- Unknown9.41M
- Unknown8.76M
- Unknown8.57M
- Unknown8.50M
- Unknown8.49M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Iovance Biotherapeutics sees analyst target raise and whale activity
Recent reports show large investors were active in IOVA shares, indicating heightened interest. Baird kept a neutral stance but lifted its price target to $11, above its prior level. The Q2 2026 earnings call highlighted ongoing clinical progress, which aligns with the analyst’s revised outlook. The stock is near the upper end of its 52‑week range.
Iovance Biotherapeutics sees analyst target raise and whale activity. Recent reports show large investors were active in IOVA shares, indicating heightened interest. Baird kept a neutral stance but lifted its price target to $11, above its prior level. The Q2 2026 earnings call highlighted ongoing clinical progress, which aligns with the analyst’s revised outlook. The stock is near the upper end of its 52‑week range.